nodes	percent_of_prediction	percent_of_DWPC	metapath
Esomeprazole—CYP2C19—Gefitinib—lung cancer	0.0899	0.176	CbGbCtD
Esomeprazole—CYP2C19—Teniposide—lung cancer	0.0872	0.17	CbGbCtD
Esomeprazole—CYP3A4—Topotecan—lung cancer	0.0475	0.0929	CbGbCtD
Esomeprazole—CYP3A4—Gefitinib—lung cancer	0.0435	0.0849	CbGbCtD
Esomeprazole—CYP3A4—Teniposide—lung cancer	0.0422	0.0824	CbGbCtD
Esomeprazole—CYP3A4—Vinorelbine—lung cancer	0.0335	0.0654	CbGbCtD
Esomeprazole—CYP3A4—Crizotinib—lung cancer	0.0267	0.0521	CbGbCtD
Esomeprazole—CYP3A4—Erlotinib—lung cancer	0.0257	0.0502	CbGbCtD
Esomeprazole—CYP3A4—Paclitaxel—lung cancer	0.0235	0.046	CbGbCtD
Esomeprazole—CYP3A4—Irinotecan—lung cancer	0.0232	0.0454	CbGbCtD
Esomeprazole—CYP3A4—Vinblastine—lung cancer	0.0206	0.0403	CbGbCtD
Esomeprazole—CYP3A4—Etoposide—lung cancer	0.0186	0.0363	CbGbCtD
Esomeprazole—CYP3A4—Docetaxel—lung cancer	0.017	0.0332	CbGbCtD
Esomeprazole—CYP3A4—Doxorubicin—lung cancer	0.0127	0.0248	CbGbCtD
Esomeprazole—Omeprazole—ABCC3—lung cancer	0.00236	0.202	CrCbGaD
Esomeprazole—Pantoprazole—ABCG2—lung cancer	0.0014	0.12	CrCbGaD
Esomeprazole—Rabeprazole—ABCG2—lung cancer	0.0014	0.12	CrCbGaD
Esomeprazole—Omeprazole—ABCG2—lung cancer	0.00114	0.0981	CrCbGaD
Esomeprazole—Rabeprazole—CYP1A1—lung cancer	0.0011	0.0942	CrCbGaD
Esomeprazole—Lansoprazole—ABCG2—lung cancer	0.00105	0.0897	CrCbGaD
Esomeprazole—Omeprazole—CYP1A1—lung cancer	0.000897	0.0768	CrCbGaD
Esomeprazole—Lansoprazole—CYP1A1—lung cancer	0.00082	0.0703	CrCbGaD
Esomeprazole—Pantoprazole—ABCB1—lung cancer	0.000585	0.0501	CrCbGaD
Esomeprazole—Omeprazole—ABCB1—lung cancer	0.000477	0.0408	CrCbGaD
Esomeprazole—Lansoprazole—ABCB1—lung cancer	0.000436	0.0373	CrCbGaD
Esomeprazole—ATP4A—Ion channel transport—RAF1—lung cancer	0.000294	0.00638	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC3—lung cancer	0.000291	0.00631	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ADCY1—lung cancer	0.00029	0.00629	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ABCG2—lung cancer	0.00029	0.00629	CbGpPWpGaD
Esomeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—lung cancer	0.000277	0.00601	CbGpPWpGaD
Esomeprazole—CYP3A4—Xenobiotics—CYP2E1—lung cancer	0.000276	0.00599	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—lung cancer	0.000273	0.00593	CbGpPWpGaD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—HPGDS—lung cancer	0.00027	0.00587	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—TF—lung cancer	0.000269	0.00585	CbGpPWpGaD
Esomeprazole—CYP3A4—Tamoxifen metabolism—CYP2E1—lung cancer	0.000265	0.00576	CbGpPWpGaD
Esomeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—lung cancer	0.000253	0.0055	CbGpPWpGaD
Esomeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—lung cancer	0.000246	0.00534	CbGpPWpGaD
Esomeprazole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—lung cancer	0.000245	0.00533	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—CYP1A1—lung cancer	0.000245	0.00532	CbGpPWpGaD
Esomeprazole—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—lung cancer	0.000237	0.00515	CbGpPWpGaD
Esomeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—lung cancer	0.000232	0.00504	CbGpPWpGaD
Esomeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—lung cancer	0.000229	0.00497	CbGpPWpGaD
Esomeprazole—CYP3A4—Estrogen metabolism—GSTM1—lung cancer	0.000227	0.00494	CbGpPWpGaD
Esomeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	0.000224	0.00487	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—lung cancer	0.000223	0.00484	CbGpPWpGaD
Esomeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP2A6—lung cancer	0.000221	0.0048	CbGpPWpGaD
Esomeprazole—CYP3A4—Estrogen metabolism—CYP1A1—lung cancer	0.000216	0.00468	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—AVP—lung cancer	0.000209	0.00455	CbGpPWpGaD
Esomeprazole—CYP3A4—Irinotecan Pathway—APC—lung cancer	0.000206	0.00448	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000203	0.00441	CbGpPWpGaD
Esomeprazole—CYP3A4—Xenobiotics—CYP1A1—lung cancer	0.000198	0.0043	CbGpPWpGaD
Esomeprazole—CYP3A4—Tamoxifen metabolism—CYP1A1—lung cancer	0.000191	0.00414	CbGpPWpGaD
Esomeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	0.00019	0.00414	CbGpPWpGaD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—lung cancer	0.000188	0.00408	CbGpPWpGaD
Esomeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP2E1—lung cancer	0.000188	0.00408	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—AVP—lung cancer	0.000187	0.00406	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—CNDP2—lung cancer	0.000184	0.00399	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTM2—lung cancer	0.000184	0.00399	CbGpPWpGaD
Esomeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	0.000182	0.00394	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTM2—lung cancer	0.000181	0.00393	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ABCB1—lung cancer	0.000181	0.00393	CbGpPWpGaD
Esomeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—lung cancer	0.00018	0.00392	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—CYP2A7—lung cancer	0.000166	0.00361	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—CYP2A7—lung cancer	0.000164	0.00356	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—APOA1—lung cancer	0.00016	0.00348	CbGpPWpGaD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—CYP1A1—lung cancer	0.000158	0.00344	CbGpPWpGaD
Esomeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	0.000154	0.00335	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTA3—lung cancer	0.000148	0.00321	CbGpPWpGaD
Esomeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—lung cancer	0.000148	0.00321	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTA3—lung cancer	0.000146	0.00317	CbGpPWpGaD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—APOA1—lung cancer	0.000143	0.0031	CbGpPWpGaD
Esomeprazole—CYP3A4—Tryptophan metabolism—CYP2E1—lung cancer	0.000142	0.00308	CbGpPWpGaD
Esomeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—lung cancer	0.000141	0.00306	CbGpPWpGaD
Esomeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	0.000137	0.00297	CbGpPWpGaD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000136	0.00295	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTA4—lung cancer	0.000135	0.00294	CbGpPWpGaD
Esomeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—lung cancer	0.000135	0.00293	CbGpPWpGaD
Esomeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	0.000135	0.00293	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTA4—lung cancer	0.000134	0.0029	CbGpPWpGaD
Esomeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—lung cancer	0.000133	0.00289	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTA2—lung cancer	0.000132	0.00287	CbGpPWpGaD
Esomeprazole—Decreased appetite—Paclitaxel—lung cancer	0.000131	0.000304	CcSEcCtD
Esomeprazole—Dry mouth—Docetaxel—lung cancer	0.00013	0.000303	CcSEcCtD
Esomeprazole—Upper respiratory tract infection—Doxorubicin—lung cancer	0.00013	0.000303	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00013	0.000302	CcSEcCtD
Esomeprazole—Fatigue—Paclitaxel—lung cancer	0.00013	0.000302	CcSEcCtD
Esomeprazole—Hepatitis—Methotrexate—lung cancer	0.00013	0.000301	CcSEcCtD
Esomeprazole—Pollakiuria—Doxorubicin—lung cancer	0.000129	0.000301	CcSEcCtD
Esomeprazole—Asthenia—Gemcitabine—lung cancer	0.000129	0.0003	CcSEcCtD
Esomeprazole—Pain—Paclitaxel—lung cancer	0.000129	0.000299	CcSEcCtD
Esomeprazole—Constipation—Paclitaxel—lung cancer	0.000129	0.000299	CcSEcCtD
Esomeprazole—Confusional state—Docetaxel—lung cancer	0.000129	0.000299	CcSEcCtD
Esomeprazole—Pharyngitis—Methotrexate—lung cancer	0.000129	0.000299	CcSEcCtD
Esomeprazole—Urinary tract disorder—Methotrexate—lung cancer	0.000128	0.000297	CcSEcCtD
Esomeprazole—Photosensitivity reaction—Doxorubicin—lung cancer	0.000128	0.000297	CcSEcCtD
Esomeprazole—Anaphylactic shock—Docetaxel—lung cancer	0.000128	0.000297	CcSEcCtD
Esomeprazole—Weight increased—Doxorubicin—lung cancer	0.000128	0.000296	CcSEcCtD
Esomeprazole—Pruritus—Gemcitabine—lung cancer	0.000127	0.000296	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—GSTA1—lung cancer	0.000127	0.00276	CbGpPWpGaD
Esomeprazole—Urethral disorder—Methotrexate—lung cancer	0.000127	0.000295	CcSEcCtD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ALB—lung cancer	0.000127	0.00276	CbGpPWpGaD
Esomeprazole—Infection—Docetaxel—lung cancer	0.000127	0.000295	CcSEcCtD
Esomeprazole—Weight decreased—Doxorubicin—lung cancer	0.000127	0.000295	CcSEcCtD
Esomeprazole—Feeling abnormal—Etoposide—lung cancer	0.000127	0.000294	CcSEcCtD
Esomeprazole—Diarrhoea—Irinotecan—lung cancer	0.000126	0.000294	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Etoposide—lung cancer	0.000126	0.000292	CcSEcCtD
Esomeprazole—Shock—Docetaxel—lung cancer	0.000126	0.000292	CcSEcCtD
Esomeprazole—Nervous system disorder—Docetaxel—lung cancer	0.000125	0.000291	CcSEcCtD
Esomeprazole—Thrombocytopenia—Docetaxel—lung cancer	0.000125	0.000291	CcSEcCtD
Esomeprazole—Infestation NOS—Doxorubicin—lung cancer	0.000125	0.00029	CcSEcCtD
Esomeprazole—Infestation—Doxorubicin—lung cancer	0.000125	0.00029	CcSEcCtD
Esomeprazole—Visual impairment—Methotrexate—lung cancer	0.000125	0.00029	CcSEcCtD
Esomeprazole—Tachycardia—Docetaxel—lung cancer	0.000125	0.00029	CcSEcCtD
Esomeprazole—Feeling abnormal—Paclitaxel—lung cancer	0.000124	0.000288	CcSEcCtD
Esomeprazole—Skin disorder—Docetaxel—lung cancer	0.000124	0.000288	CcSEcCtD
Esomeprazole—Stevens-Johnson syndrome—Doxorubicin—lung cancer	0.000124	0.000288	CcSEcCtD
Esomeprazole—Hypersensitivity—Cisplatin—lung cancer	0.000124	0.000287	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Paclitaxel—lung cancer	0.000123	0.000286	CcSEcCtD
Esomeprazole—Diarrhoea—Gemcitabine—lung cancer	0.000123	0.000286	CcSEcCtD
Esomeprazole—Renal failure—Doxorubicin—lung cancer	0.000123	0.000285	CcSEcCtD
Esomeprazole—Erythema multiforme—Methotrexate—lung cancer	0.000122	0.000285	CcSEcCtD
Esomeprazole—Dizziness—Irinotecan—lung cancer	0.000122	0.000284	CcSEcCtD
Esomeprazole—Urticaria—Etoposide—lung cancer	0.000122	0.000284	CcSEcCtD
Esomeprazole—Jaundice—Doxorubicin—lung cancer	0.000122	0.000283	CcSEcCtD
Esomeprazole—Stomatitis—Doxorubicin—lung cancer	0.000122	0.000283	CcSEcCtD
Esomeprazole—Anorexia—Docetaxel—lung cancer	0.000122	0.000283	CcSEcCtD
Esomeprazole—Abdominal pain—Etoposide—lung cancer	0.000121	0.000282	CcSEcCtD
Esomeprazole—Body temperature increased—Etoposide—lung cancer	0.000121	0.000282	CcSEcCtD
Esomeprazole—Conjunctivitis—Doxorubicin—lung cancer	0.000121	0.000282	CcSEcCtD
Esomeprazole—Urinary tract infection—Doxorubicin—lung cancer	0.000121	0.000282	CcSEcCtD
Esomeprazole—Eye disorder—Methotrexate—lung cancer	0.000121	0.000281	CcSEcCtD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000121	0.00263	CbGpPWpGaD
Esomeprazole—Tinnitus—Methotrexate—lung cancer	0.000121	0.000281	CcSEcCtD
Esomeprazole—Asthenia—Cisplatin—lung cancer	0.00012	0.00028	CcSEcCtD
Esomeprazole—CYP2C19—Metapathway biotransformation—AKR1C1—lung cancer	0.00012	0.00261	CbGpPWpGaD
Esomeprazole—Urticaria—Paclitaxel—lung cancer	0.00012	0.000278	CcSEcCtD
Esomeprazole—Haematuria—Doxorubicin—lung cancer	0.000119	0.000277	CcSEcCtD
Esomeprazole—Body temperature increased—Paclitaxel—lung cancer	0.000119	0.000277	CcSEcCtD
Esomeprazole—Abdominal pain—Paclitaxel—lung cancer	0.000119	0.000277	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—UGT1A1—lung cancer	0.000118	0.00257	CbGpPWpGaD
Esomeprazole—Hepatobiliary disease—Doxorubicin—lung cancer	0.000118	0.000275	CcSEcCtD
Esomeprazole—Epistaxis—Doxorubicin—lung cancer	0.000118	0.000274	CcSEcCtD
Esomeprazole—Vomiting—Irinotecan—lung cancer	0.000117	0.000273	CcSEcCtD
Esomeprazole—Sinusitis—Doxorubicin—lung cancer	0.000117	0.000272	CcSEcCtD
Esomeprazole—Immune system disorder—Methotrexate—lung cancer	0.000117	0.000272	CcSEcCtD
Esomeprazole—Mediastinal disorder—Methotrexate—lung cancer	0.000117	0.000271	CcSEcCtD
Esomeprazole—CYP2C19—Metapathway biotransformation—UGT1A1—lung cancer	0.000117	0.00253	CbGpPWpGaD
Esomeprazole—Agranulocytosis—Doxorubicin—lung cancer	0.000117	0.000271	CcSEcCtD
Esomeprazole—Rash—Irinotecan—lung cancer	0.000116	0.000271	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—COL4A3BP—lung cancer	0.000116	0.00253	CbGpPWpGaD
Esomeprazole—Dermatitis—Irinotecan—lung cancer	0.000116	0.00027	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000116	0.00027	CcSEcCtD
Esomeprazole—Chills—Methotrexate—lung cancer	0.000116	0.00027	CcSEcCtD
Esomeprazole—Headache—Irinotecan—lung cancer	0.000116	0.000269	CcSEcCtD
Esomeprazole—Insomnia—Docetaxel—lung cancer	0.000116	0.000268	CcSEcCtD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—RAF1—lung cancer	0.000115	0.00249	CbGpPWpGaD
Esomeprazole—Diarrhoea—Cisplatin—lung cancer	0.000115	0.000267	CcSEcCtD
Esomeprazole—Paraesthesia—Docetaxel—lung cancer	0.000115	0.000266	CcSEcCtD
Esomeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	0.000115	0.00249	CbGpPWpGaD
Esomeprazole—Alopecia—Methotrexate—lung cancer	0.000114	0.000266	CcSEcCtD
Esomeprazole—Vomiting—Gemcitabine—lung cancer	0.000114	0.000266	CcSEcCtD
Esomeprazole—Bradycardia—Doxorubicin—lung cancer	0.000114	0.000265	CcSEcCtD
Esomeprazole—Dyspnoea—Docetaxel—lung cancer	0.000114	0.000265	CcSEcCtD
Esomeprazole—CYP3A4—Tryptophan metabolism—CAT—lung cancer	0.000114	0.00247	CbGpPWpGaD
Esomeprazole—Somnolence—Docetaxel—lung cancer	0.000114	0.000264	CcSEcCtD
Esomeprazole—Mental disorder—Methotrexate—lung cancer	0.000114	0.000264	CcSEcCtD
Esomeprazole—Rash—Gemcitabine—lung cancer	0.000113	0.000264	CcSEcCtD
Esomeprazole—Dermatitis—Gemcitabine—lung cancer	0.000113	0.000263	CcSEcCtD
Esomeprazole—Hypersensitivity—Etoposide—lung cancer	0.000113	0.000263	CcSEcCtD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ALB—lung cancer	0.000113	0.00246	CbGpPWpGaD
Esomeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—lung cancer	0.000113	0.00245	CbGpPWpGaD
Esomeprazole—Malnutrition—Methotrexate—lung cancer	0.000113	0.000262	CcSEcCtD
Esomeprazole—Headache—Gemcitabine—lung cancer	0.000113	0.000262	CcSEcCtD
Esomeprazole—Rhinitis—Doxorubicin—lung cancer	0.000112	0.000261	CcSEcCtD
Esomeprazole—Dyspepsia—Docetaxel—lung cancer	0.000112	0.000261	CcSEcCtD
Esomeprazole—Hepatitis—Doxorubicin—lung cancer	0.000112	0.000261	CcSEcCtD
Esomeprazole—Hypoaesthesia—Doxorubicin—lung cancer	0.000112	0.000259	CcSEcCtD
Esomeprazole—Pharyngitis—Doxorubicin—lung cancer	0.000111	0.000259	CcSEcCtD
Esomeprazole—Decreased appetite—Docetaxel—lung cancer	0.000111	0.000258	CcSEcCtD
Esomeprazole—Hypersensitivity—Paclitaxel—lung cancer	0.000111	0.000258	CcSEcCtD
Esomeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	0.000111	0.00241	CbGpPWpGaD
Esomeprazole—Urinary tract disorder—Doxorubicin—lung cancer	0.000111	0.000257	CcSEcCtD
Esomeprazole—Oedema peripheral—Doxorubicin—lung cancer	0.000111	0.000257	CcSEcCtD
Esomeprazole—Dysgeusia—Methotrexate—lung cancer	0.00011	0.000257	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—CNDP2—lung cancer	0.00011	0.0024	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTM2—lung cancer	0.00011	0.0024	CbGpPWpGaD
Esomeprazole—Gastrointestinal disorder—Docetaxel—lung cancer	0.00011	0.000256	CcSEcCtD
Esomeprazole—Asthenia—Etoposide—lung cancer	0.00011	0.000256	CcSEcCtD
Esomeprazole—Connective tissue disorder—Doxorubicin—lung cancer	0.00011	0.000256	CcSEcCtD
Esomeprazole—Fatigue—Docetaxel—lung cancer	0.00011	0.000256	CcSEcCtD
Esomeprazole—Urethral disorder—Doxorubicin—lung cancer	0.00011	0.000256	CcSEcCtD
Esomeprazole—Nausea—Irinotecan—lung cancer	0.00011	0.000255	CcSEcCtD
Esomeprazole—Pain—Docetaxel—lung cancer	0.000109	0.000254	CcSEcCtD
Esomeprazole—Constipation—Docetaxel—lung cancer	0.000109	0.000254	CcSEcCtD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	0.000109	0.00237	CbGpPWpGaD
Esomeprazole—Back pain—Methotrexate—lung cancer	0.000109	0.000253	CcSEcCtD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTM2—lung cancer	0.000109	0.00237	CbGpPWpGaD
Esomeprazole—Pruritus—Etoposide—lung cancer	0.000109	0.000253	CcSEcCtD
Esomeprazole—Visual impairment—Doxorubicin—lung cancer	0.000108	0.000251	CcSEcCtD
Esomeprazole—Asthenia—Paclitaxel—lung cancer	0.000108	0.000251	CcSEcCtD
Esomeprazole—Nausea—Gemcitabine—lung cancer	0.000107	0.000248	CcSEcCtD
Esomeprazole—Vomiting—Cisplatin—lung cancer	0.000107	0.000248	CcSEcCtD
Esomeprazole—Pruritus—Paclitaxel—lung cancer	0.000107	0.000248	CcSEcCtD
Esomeprazole—Vision blurred—Methotrexate—lung cancer	0.000106	0.000247	CcSEcCtD
Esomeprazole—Erythema multiforme—Doxorubicin—lung cancer	0.000106	0.000246	CcSEcCtD
Esomeprazole—Rash—Cisplatin—lung cancer	0.000106	0.000246	CcSEcCtD
Esomeprazole—Dermatitis—Cisplatin—lung cancer	0.000106	0.000245	CcSEcCtD
Esomeprazole—Feeling abnormal—Docetaxel—lung cancer	0.000105	0.000245	CcSEcCtD
Esomeprazole—Diarrhoea—Etoposide—lung cancer	0.000105	0.000244	CcSEcCtD
Esomeprazole—Eye disorder—Doxorubicin—lung cancer	0.000105	0.000244	CcSEcCtD
Esomeprazole—Ill-defined disorder—Methotrexate—lung cancer	0.000105	0.000243	CcSEcCtD
Esomeprazole—Tinnitus—Doxorubicin—lung cancer	0.000105	0.000243	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Docetaxel—lung cancer	0.000104	0.000243	CcSEcCtD
Esomeprazole—Anaemia—Methotrexate—lung cancer	0.000104	0.000242	CcSEcCtD
Esomeprazole—Flushing—Doxorubicin—lung cancer	0.000104	0.000242	CcSEcCtD
Esomeprazole—Diarrhoea—Paclitaxel—lung cancer	0.000103	0.00024	CcSEcCtD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—RAF1—lung cancer	0.000102	0.00222	CbGpPWpGaD
Esomeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	0.000102	0.00222	CbGpPWpGaD
Esomeprazole—CYP3A4—Tryptophan metabolism—CYP1A1—lung cancer	0.000102	0.00221	CbGpPWpGaD
Esomeprazole—Malaise—Methotrexate—lung cancer	0.000102	0.000236	CcSEcCtD
Esomeprazole—Dizziness—Etoposide—lung cancer	0.000102	0.000236	CcSEcCtD
Esomeprazole—Immune system disorder—Doxorubicin—lung cancer	0.000101	0.000235	CcSEcCtD
Esomeprazole—Vertigo—Methotrexate—lung cancer	0.000101	0.000235	CcSEcCtD
Esomeprazole—Mediastinal disorder—Doxorubicin—lung cancer	0.000101	0.000235	CcSEcCtD
Esomeprazole—Body temperature increased—Docetaxel—lung cancer	0.000101	0.000235	CcSEcCtD
Esomeprazole—Abdominal pain—Docetaxel—lung cancer	0.000101	0.000235	CcSEcCtD
Esomeprazole—Leukopenia—Methotrexate—lung cancer	0.000101	0.000235	CcSEcCtD
Esomeprazole—Chills—Doxorubicin—lung cancer	0.000101	0.000234	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—HPGDS—lung cancer	0.000101	0.00219	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—CYP2A7—lung cancer	9.99e-05	0.00217	CbGpPWpGaD
Esomeprazole—Dizziness—Paclitaxel—lung cancer	9.96e-05	0.000231	CcSEcCtD
Esomeprazole—Nausea—Cisplatin—lung cancer	9.96e-05	0.000231	CcSEcCtD
Esomeprazole—Alopecia—Doxorubicin—lung cancer	9.91e-05	0.00023	CcSEcCtD
Esomeprazole—CYP3A4—Metapathway biotransformation—CYP2A7—lung cancer	9.85e-05	0.00214	CbGpPWpGaD
Esomeprazole—Cough—Methotrexate—lung cancer	9.84e-05	0.000229	CcSEcCtD
Esomeprazole—Mental disorder—Doxorubicin—lung cancer	9.83e-05	0.000228	CcSEcCtD
Esomeprazole—Vomiting—Etoposide—lung cancer	9.77e-05	0.000227	CcSEcCtD
Esomeprazole—Malnutrition—Doxorubicin—lung cancer	9.77e-05	0.000227	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—GSTT1—lung cancer	9.76e-05	0.00212	CbGpPWpGaD
Esomeprazole—Rash—Etoposide—lung cancer	9.69e-05	0.000225	CcSEcCtD
Esomeprazole—Dermatitis—Etoposide—lung cancer	9.68e-05	0.000225	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—CYP2A6—lung cancer	9.65e-05	0.0021	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GCLC—lung cancer	9.65e-05	0.0021	CbGpPWpGaD
Esomeprazole—Headache—Etoposide—lung cancer	9.63e-05	0.000224	CcSEcCtD
Esomeprazole—Flatulence—Doxorubicin—lung cancer	9.62e-05	0.000224	CcSEcCtD
Esomeprazole—Myalgia—Methotrexate—lung cancer	9.6e-05	0.000223	CcSEcCtD
Esomeprazole—Arthralgia—Methotrexate—lung cancer	9.6e-05	0.000223	CcSEcCtD
Esomeprazole—Chest pain—Methotrexate—lung cancer	9.6e-05	0.000223	CcSEcCtD
Esomeprazole—Tension—Doxorubicin—lung cancer	9.58e-05	0.000223	CcSEcCtD
Esomeprazole—Vomiting—Paclitaxel—lung cancer	9.58e-05	0.000223	CcSEcCtD
Esomeprazole—Dysgeusia—Doxorubicin—lung cancer	9.56e-05	0.000222	CcSEcCtD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	9.54e-05	0.000222	CcSEcCtD
Esomeprazole—Rash—Paclitaxel—lung cancer	9.5e-05	0.000221	CcSEcCtD
Esomeprazole—Dermatitis—Paclitaxel—lung cancer	9.49e-05	0.000221	CcSEcCtD
Esomeprazole—Discomfort—Methotrexate—lung cancer	9.49e-05	0.00022	CcSEcCtD
Esomeprazole—Nervousness—Doxorubicin—lung cancer	9.48e-05	0.00022	CcSEcCtD
Esomeprazole—Back pain—Doxorubicin—lung cancer	9.45e-05	0.000219	CcSEcCtD
Esomeprazole—Headache—Paclitaxel—lung cancer	9.44e-05	0.000219	CcSEcCtD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—lung cancer	9.42e-05	0.00205	CbGpPWpGaD
Esomeprazole—Hypersensitivity—Docetaxel—lung cancer	9.41e-05	0.000219	CcSEcCtD
Esomeprazole—Muscle spasms—Doxorubicin—lung cancer	9.39e-05	0.000218	CcSEcCtD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	9.28e-05	0.00202	CbGpPWpGaD
Esomeprazole—Confusional state—Methotrexate—lung cancer	9.28e-05	0.000216	CcSEcCtD
Esomeprazole—Anaphylactic shock—Methotrexate—lung cancer	9.2e-05	0.000214	CcSEcCtD
Esomeprazole—Vision blurred—Doxorubicin—lung cancer	9.2e-05	0.000214	CcSEcCtD
Esomeprazole—Asthenia—Docetaxel—lung cancer	9.16e-05	0.000213	CcSEcCtD
Esomeprazole—Infection—Methotrexate—lung cancer	9.14e-05	0.000212	CcSEcCtD
Esomeprazole—Nausea—Etoposide—lung cancer	9.13e-05	0.000212	CcSEcCtD
Esomeprazole—Ill-defined disorder—Doxorubicin—lung cancer	9.06e-05	0.000211	CcSEcCtD
Esomeprazole—Pruritus—Docetaxel—lung cancer	9.04e-05	0.00021	CcSEcCtD
Esomeprazole—Nervous system disorder—Methotrexate—lung cancer	9.03e-05	0.00021	CcSEcCtD
Esomeprazole—Anaemia—Doxorubicin—lung cancer	9.03e-05	0.00021	CcSEcCtD
Esomeprazole—Thrombocytopenia—Methotrexate—lung cancer	9.01e-05	0.000209	CcSEcCtD
Esomeprazole—Agitation—Doxorubicin—lung cancer	8.97e-05	0.000209	CcSEcCtD
Esomeprazole—Nausea—Paclitaxel—lung cancer	8.95e-05	0.000208	CcSEcCtD
Esomeprazole—Skin disorder—Methotrexate—lung cancer	8.94e-05	0.000208	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—GSTA3—lung cancer	8.9e-05	0.00193	CbGpPWpGaD
Esomeprazole—Hyperhidrosis—Methotrexate—lung cancer	8.9e-05	0.000207	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PLBD1—lung cancer	8.82e-05	0.00192	CbGpPWpGaD
Esomeprazole—Malaise—Doxorubicin—lung cancer	8.81e-05	0.000205	CcSEcCtD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTA3—lung cancer	8.78e-05	0.00191	CbGpPWpGaD
Esomeprazole—Vertigo—Doxorubicin—lung cancer	8.77e-05	0.000204	CcSEcCtD
Esomeprazole—Anorexia—Methotrexate—lung cancer	8.77e-05	0.000204	CcSEcCtD
Esomeprazole—Leukopenia—Doxorubicin—lung cancer	8.74e-05	0.000203	CcSEcCtD
Esomeprazole—Diarrhoea—Docetaxel—lung cancer	8.74e-05	0.000203	CcSEcCtD
Esomeprazole—Palpitations—Doxorubicin—lung cancer	8.63e-05	0.000201	CcSEcCtD
Esomeprazole—Cough—Doxorubicin—lung cancer	8.52e-05	0.000198	CcSEcCtD
Esomeprazole—Dizziness—Docetaxel—lung cancer	8.44e-05	0.000196	CcSEcCtD
Esomeprazole—Hypertension—Doxorubicin—lung cancer	8.43e-05	0.000196	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Methotrexate—lung cancer	8.39e-05	0.000195	CcSEcCtD
Esomeprazole—Insomnia—Methotrexate—lung cancer	8.32e-05	0.000193	CcSEcCtD
Esomeprazole—Chest pain—Doxorubicin—lung cancer	8.31e-05	0.000193	CcSEcCtD
Esomeprazole—Myalgia—Doxorubicin—lung cancer	8.31e-05	0.000193	CcSEcCtD
Esomeprazole—Arthralgia—Doxorubicin—lung cancer	8.31e-05	0.000193	CcSEcCtD
Esomeprazole—Anxiety—Doxorubicin—lung cancer	8.29e-05	0.000193	CcSEcCtD
Esomeprazole—CYP2C19—Phase 1 - Functionalization of compounds—POMC—lung cancer	8.27e-05	0.0018	CbGpPWpGaD
Esomeprazole—Paraesthesia—Methotrexate—lung cancer	8.27e-05	0.000192	CcSEcCtD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	8.26e-05	0.000192	CcSEcCtD
Esomeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	8.23e-05	0.00179	CbGpPWpGaD
Esomeprazole—Discomfort—Doxorubicin—lung cancer	8.21e-05	0.000191	CcSEcCtD
Esomeprazole—Dyspnoea—Methotrexate—lung cancer	8.21e-05	0.000191	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—CYP2E1—lung cancer	8.2e-05	0.00178	CbGpPWpGaD
Esomeprazole—Somnolence—Methotrexate—lung cancer	8.18e-05	0.00019	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—GSTA4—lung cancer	8.14e-05	0.00177	CbGpPWpGaD
Esomeprazole—Dry mouth—Doxorubicin—lung cancer	8.13e-05	0.000189	CcSEcCtD
Esomeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—lung cancer	8.12e-05	0.00176	CbGpPWpGaD
Esomeprazole—Vomiting—Docetaxel—lung cancer	8.12e-05	0.000189	CcSEcCtD
Esomeprazole—Dyspepsia—Methotrexate—lung cancer	8.1e-05	0.000188	CcSEcCtD
Esomeprazole—CYP2C19—Metapathway biotransformation—CYP2E1—lung cancer	8.09e-05	0.00176	CbGpPWpGaD
Esomeprazole—Rash—Docetaxel—lung cancer	8.05e-05	0.000187	CcSEcCtD
Esomeprazole—Dermatitis—Docetaxel—lung cancer	8.04e-05	0.000187	CcSEcCtD
Esomeprazole—Confusional state—Doxorubicin—lung cancer	8.04e-05	0.000187	CcSEcCtD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTA4—lung cancer	8.03e-05	0.00174	CbGpPWpGaD
Esomeprazole—Decreased appetite—Methotrexate—lung cancer	8e-05	0.000186	CcSEcCtD
Esomeprazole—Headache—Docetaxel—lung cancer	8e-05	0.000186	CcSEcCtD
Esomeprazole—Anaphylactic shock—Doxorubicin—lung cancer	7.97e-05	0.000185	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Methotrexate—lung cancer	7.95e-05	0.000185	CcSEcCtD
Esomeprazole—Fatigue—Methotrexate—lung cancer	7.94e-05	0.000184	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—GSTA2—lung cancer	7.93e-05	0.00172	CbGpPWpGaD
Esomeprazole—Infection—Doxorubicin—lung cancer	7.92e-05	0.000184	CcSEcCtD
Esomeprazole—Pain—Methotrexate—lung cancer	7.87e-05	0.000183	CcSEcCtD
Esomeprazole—Shock—Doxorubicin—lung cancer	7.84e-05	0.000182	CcSEcCtD
Esomeprazole—Nervous system disorder—Doxorubicin—lung cancer	7.82e-05	0.000182	CcSEcCtD
Esomeprazole—Thrombocytopenia—Doxorubicin—lung cancer	7.8e-05	0.000181	CcSEcCtD
Esomeprazole—Tachycardia—Doxorubicin—lung cancer	7.78e-05	0.000181	CcSEcCtD
Esomeprazole—Skin disorder—Doxorubicin—lung cancer	7.74e-05	0.00018	CcSEcCtD
Esomeprazole—Hyperhidrosis—Doxorubicin—lung cancer	7.7e-05	0.000179	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—GSTA1—lung cancer	7.65e-05	0.00166	CbGpPWpGaD
Esomeprazole—Anorexia—Doxorubicin—lung cancer	7.6e-05	0.000177	CcSEcCtD
Esomeprazole—Nausea—Docetaxel—lung cancer	7.59e-05	0.000176	CcSEcCtD
Esomeprazole—Feeling abnormal—Methotrexate—lung cancer	7.58e-05	0.000176	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Methotrexate—lung cancer	7.53e-05	0.000175	CcSEcCtD
Esomeprazole—Urticaria—Methotrexate—lung cancer	7.31e-05	0.00017	CcSEcCtD
Esomeprazole—Abdominal pain—Methotrexate—lung cancer	7.28e-05	0.000169	CcSEcCtD
Esomeprazole—Body temperature increased—Methotrexate—lung cancer	7.28e-05	0.000169	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Doxorubicin—lung cancer	7.26e-05	0.000169	CcSEcCtD
Esomeprazole—CYP3A4—Metapathway biotransformation—AKR1C1—lung cancer	7.23e-05	0.00157	CbGpPWpGaD
Esomeprazole—Insomnia—Doxorubicin—lung cancer	7.21e-05	0.000167	CcSEcCtD
Esomeprazole—Paraesthesia—Doxorubicin—lung cancer	7.16e-05	0.000166	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—UGT1A1—lung cancer	7.12e-05	0.00155	CbGpPWpGaD
Esomeprazole—Dyspnoea—Doxorubicin—lung cancer	7.11e-05	0.000165	CcSEcCtD
Esomeprazole—Somnolence—Doxorubicin—lung cancer	7.09e-05	0.000165	CcSEcCtD
Esomeprazole—CYP3A4—Metapathway biotransformation—UGT1A1—lung cancer	7.02e-05	0.00152	CbGpPWpGaD
Esomeprazole—Dyspepsia—Doxorubicin—lung cancer	7.02e-05	0.000163	CcSEcCtD
Esomeprazole—Decreased appetite—Doxorubicin—lung cancer	6.93e-05	0.000161	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Doxorubicin—lung cancer	6.88e-05	0.00016	CcSEcCtD
Esomeprazole—Fatigue—Doxorubicin—lung cancer	6.87e-05	0.00016	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—MTMR3—lung cancer	6.86e-05	0.00149	CbGpPWpGaD
Esomeprazole—Constipation—Doxorubicin—lung cancer	6.82e-05	0.000158	CcSEcCtD
Esomeprazole—Pain—Doxorubicin—lung cancer	6.82e-05	0.000158	CcSEcCtD
Esomeprazole—Hypersensitivity—Methotrexate—lung cancer	6.78e-05	0.000158	CcSEcCtD
Esomeprazole—CYP2C19—Biological oxidations—GSTP1—lung cancer	6.76e-05	0.00147	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTP1—lung cancer	6.67e-05	0.00145	CbGpPWpGaD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	6.67e-05	0.00145	CbGpPWpGaD
Esomeprazole—Asthenia—Methotrexate—lung cancer	6.6e-05	0.000153	CcSEcCtD
Esomeprazole—Feeling abnormal—Doxorubicin—lung cancer	6.57e-05	0.000153	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Doxorubicin—lung cancer	6.52e-05	0.000151	CcSEcCtD
Esomeprazole—Pruritus—Methotrexate—lung cancer	6.51e-05	0.000151	CcSEcCtD
Esomeprazole—Urticaria—Doxorubicin—lung cancer	6.33e-05	0.000147	CcSEcCtD
Esomeprazole—Body temperature increased—Doxorubicin—lung cancer	6.3e-05	0.000146	CcSEcCtD
Esomeprazole—Abdominal pain—Doxorubicin—lung cancer	6.3e-05	0.000146	CcSEcCtD
Esomeprazole—Diarrhoea—Methotrexate—lung cancer	6.3e-05	0.000146	CcSEcCtD
Esomeprazole—CYP3A4—Tryptophan metabolism—MDM2—lung cancer	6.28e-05	0.00136	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTM1—lung cancer	6.22e-05	0.00135	CbGpPWpGaD
Esomeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	6.14e-05	0.00133	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTM1—lung cancer	6.13e-05	0.00133	CbGpPWpGaD
Esomeprazole—Dizziness—Methotrexate—lung cancer	6.09e-05	0.000141	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—HPGDS—lung cancer	6.05e-05	0.00131	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—CYP1A1—lung cancer	5.89e-05	0.00128	CbGpPWpGaD
Esomeprazole—Hypersensitivity—Doxorubicin—lung cancer	5.87e-05	0.000136	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—GSTT1—lung cancer	5.87e-05	0.00127	CbGpPWpGaD
Esomeprazole—Vomiting—Methotrexate—lung cancer	5.85e-05	0.000136	CcSEcCtD
Esomeprazole—CYP2C19—Metapathway biotransformation—CYP1A1—lung cancer	5.81e-05	0.00126	CbGpPWpGaD
Esomeprazole—Rash—Methotrexate—lung cancer	5.8e-05	0.000135	CcSEcCtD
Esomeprazole—CYP3A4—Biological oxidations—CYP2A6—lung cancer	5.8e-05	0.00126	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GCLC—lung cancer	5.8e-05	0.00126	CbGpPWpGaD
Esomeprazole—Dermatitis—Methotrexate—lung cancer	5.8e-05	0.000135	CcSEcCtD
Esomeprazole—Headache—Methotrexate—lung cancer	5.77e-05	0.000134	CcSEcCtD
Esomeprazole—Asthenia—Doxorubicin—lung cancer	5.72e-05	0.000133	CcSEcCtD
Esomeprazole—Pruritus—Doxorubicin—lung cancer	5.64e-05	0.000131	CcSEcCtD
Esomeprazole—Nausea—Methotrexate—lung cancer	5.47e-05	0.000127	CcSEcCtD
Esomeprazole—Diarrhoea—Doxorubicin—lung cancer	5.45e-05	0.000127	CcSEcCtD
Esomeprazole—Dizziness—Doxorubicin—lung cancer	5.27e-05	0.000122	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism—COL4A3BP—lung cancer	5.18e-05	0.00113	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—AZIN2—lung cancer	5.18e-05	0.00113	CbGpPWpGaD
Esomeprazole—Vomiting—Doxorubicin—lung cancer	5.07e-05	0.000118	CcSEcCtD
Esomeprazole—Rash—Doxorubicin—lung cancer	5.03e-05	0.000117	CcSEcCtD
Esomeprazole—Dermatitis—Doxorubicin—lung cancer	5.02e-05	0.000117	CcSEcCtD
Esomeprazole—Headache—Doxorubicin—lung cancer	4.99e-05	0.000116	CcSEcCtD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—POMC—lung cancer	4.97e-05	0.00108	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—CYP2E1—lung cancer	4.93e-05	0.00107	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—CYP2E1—lung cancer	4.86e-05	0.00106	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—ABCC3—lung cancer	4.83e-05	0.00105	CbGpPWpGaD
Esomeprazole—Nausea—Doxorubicin—lung cancer	4.73e-05	0.00011	CcSEcCtD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—lung cancer	4.68e-05	0.00102	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ATP5H—lung cancer	4.41e-05	0.000957	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—POMC—lung cancer	4.39e-05	0.000954	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTP1—lung cancer	4.07e-05	0.000883	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—NCOA3—lung cancer	4.05e-05	0.00088	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTP1—lung cancer	4.01e-05	0.000871	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PLBD1—lung cancer	3.93e-05	0.000853	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	3.86e-05	0.000839	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTM1—lung cancer	3.74e-05	0.000812	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTM1—lung cancer	3.69e-05	0.000801	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—HSD17B10—lung cancer	3.59e-05	0.00078	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—CYP1A1—lung cancer	3.54e-05	0.00077	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—CYP1A1—lung cancer	3.49e-05	0.000759	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CKB—lung cancer	3.34e-05	0.000725	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTM2—lung cancer	3.14e-05	0.000682	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CNDP2—lung cancer	3.14e-05	0.000682	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—COL4A3BP—lung cancer	3.12e-05	0.000677	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—AZIN2—lung cancer	3.12e-05	0.000677	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—MTMR3—lung cancer	3.05e-05	0.000663	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PGAM1—lung cancer	2.98e-05	0.000647	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CYP2A7—lung cancer	2.84e-05	0.000617	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—SDC4—lung cancer	2.78e-05	0.000604	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ATP5H—lung cancer	2.65e-05	0.000576	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—POMC—lung cancer	2.64e-05	0.000574	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—RRM1—lung cancer	2.53e-05	0.00055	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTA3—lung cancer	2.53e-05	0.00055	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—B4GALT5—lung cancer	2.38e-05	0.000517	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PLBD1—lung cancer	2.36e-05	0.000513	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTA4—lung cancer	2.32e-05	0.000503	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	2.26e-05	0.000491	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTA2—lung cancer	2.26e-05	0.00049	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTA1—lung cancer	2.18e-05	0.000473	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—HSD17B10—lung cancer	2.16e-05	0.000469	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ABCC3—lung cancer	2.15e-05	0.000467	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—AKR1C1—lung cancer	2.08e-05	0.000453	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—UGT1A1—lung cancer	2.02e-05	0.00044	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CKB—lung cancer	2.01e-05	0.000436	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GNG11—lung cancer	1.95e-05	0.000424	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—lung cancer	1.94e-05	0.000422	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTM2—lung cancer	1.89e-05	0.00041	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CNDP2—lung cancer	1.89e-05	0.00041	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ALDOA—lung cancer	1.86e-05	0.000404	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—MTMR3—lung cancer	1.84e-05	0.000399	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—NCOA3—lung cancer	1.8e-05	0.000392	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PGAM1—lung cancer	1.79e-05	0.000389	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.77e-05	0.000385	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ADCY1—lung cancer	1.75e-05	0.000381	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ABCG2—lung cancer	1.75e-05	0.000381	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ENO2—lung cancer	1.72e-05	0.000374	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—HPGDS—lung cancer	1.72e-05	0.000374	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PPP2R1B—lung cancer	1.71e-05	0.000371	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CYP2A7—lung cancer	1.71e-05	0.000371	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.69e-05	0.000366	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—SDC4—lung cancer	1.67e-05	0.000363	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTT1—lung cancer	1.67e-05	0.000362	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GCLC—lung cancer	1.65e-05	0.000358	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CYP2A6—lung cancer	1.65e-05	0.000358	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.64e-05	0.000357	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ENO1—lung cancer	1.56e-05	0.00034	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.56e-05	0.000338	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.54e-05	0.000334	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—RRM1—lung cancer	1.52e-05	0.000331	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTA3—lung cancer	1.52e-05	0.000331	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—B4GALT5—lung cancer	1.43e-05	0.000311	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CYP2E1—lung cancer	1.4e-05	0.000305	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTA4—lung cancer	1.39e-05	0.000302	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—NQO1—lung cancer	1.39e-05	0.000301	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.36e-05	0.000295	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTA2—lung cancer	1.36e-05	0.000295	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.35e-05	0.000292	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTA1—lung cancer	1.31e-05	0.000284	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ABCC3—lung cancer	1.29e-05	0.000281	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—AKR1C1—lung cancer	1.25e-05	0.000272	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—STK11—lung cancer	1.25e-05	0.000272	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—UGT1A1—lung cancer	1.22e-05	0.000264	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.17e-05	0.000255	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GNG11—lung cancer	1.17e-05	0.000255	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTP1—lung cancer	1.16e-05	0.000251	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CAT—lung cancer	1.13e-05	0.000244	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.12e-05	0.000243	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ALDOA—lung cancer	1.12e-05	0.000243	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ABCB1—lung cancer	1.09e-05	0.000238	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—NCOA3—lung cancer	1.08e-05	0.000236	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—TYMS—lung cancer	1.08e-05	0.000234	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTM1—lung cancer	1.06e-05	0.000231	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ADCY1—lung cancer	1.06e-05	0.000229	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ABCG2—lung cancer	1.06e-05	0.000229	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—HPGDS—lung cancer	1.03e-05	0.000225	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ENO2—lung cancer	1.03e-05	0.000225	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.03e-05	0.000223	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CYP1A1—lung cancer	1.01e-05	0.000219	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTT1—lung cancer	1e-05	0.000218	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ERCC2—lung cancer	9.99e-06	0.000217	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GCLC—lung cancer	9.92e-06	0.000215	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CYP2A6—lung cancer	9.92e-06	0.000215	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ENO1—lung cancer	9.4e-06	0.000204	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—APOA1—lung cancer	8.65e-06	0.000188	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CYP2E1—lung cancer	8.43e-06	0.000183	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—NQO1—lung cancer	8.34e-06	0.000181	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	8.28e-06	0.00018	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CG—lung cancer	7.89e-06	0.000171	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—STK11—lung cancer	7.52e-06	0.000163	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—POMC—lung cancer	7.51e-06	0.000163	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CREBBP—lung cancer	7.32e-06	0.000159	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTP1—lung cancer	6.96e-06	0.000151	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CD—lung cancer	6.94e-06	0.000151	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—ALB—lung cancer	6.85e-06	0.000149	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CAT—lung cancer	6.77e-06	0.000147	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ABCB1—lung cancer	6.58e-06	0.000143	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—TYMS—lung cancer	6.47e-06	0.00014	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTM1—lung cancer	6.39e-06	0.000139	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CYP1A1—lung cancer	6.06e-06	0.000132	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CB—lung cancer	6.05e-06	0.000131	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ERCC2—lung cancer	6.01e-06	0.000131	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PTGS2—lung cancer	5.99e-06	0.00013	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PTEN—lung cancer	5.23e-06	0.000114	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—APOA1—lung cancer	5.2e-06	0.000113	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—EP300—lung cancer	4.98e-06	0.000108	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CG—lung cancer	4.75e-06	0.000103	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—POMC—lung cancer	4.52e-06	9.81e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CREBBP—lung cancer	4.4e-06	9.56e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CD—lung cancer	4.17e-06	9.06e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—ALB—lung cancer	4.12e-06	8.95e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CA—lung cancer	3.69e-06	8.01e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CB—lung cancer	3.64e-06	7.9e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PTGS2—lung cancer	3.6e-06	7.83e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PTEN—lung cancer	3.14e-06	6.83e-05	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—AKT1—lung cancer	3.01e-06	6.54e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—EP300—lung cancer	3e-06	6.51e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CA—lung cancer	2.22e-06	4.82e-05	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—AKT1—lung cancer	1.81e-06	3.93e-05	CbGpPWpGaD
